Clik here to view.
Lilly follows the trend of new AI hires; Pfizer fills key UK position as...
Thomas Fuchs → Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief AI officer on Oct. 21 and comes from the Icahn School of...
View ArticleExclusive: PhRMA attacks federal government's response to rebate model for 340B
The pharma industry’s DC-based lobbying group urged the federal government on Friday to get on board with alternative models for 340B drug price discounts. In a letter to the Health Resources and...
View ArticleClik here to view.
VC firm targets $35M second fund to back startups led by scientists
A small venture capital firm that backs up-and-coming scientists plans to raise a $35 million second fund, three years after coming onto the scene. SciFounders, based in the San Francisco Bay Area, is...
View ArticleTurnstone rejigs staff and exec team, eases preclinical work as cash runs low
Just over a year after going public, Turnstone Biologics is axing staff, adjusting its leadership team and changing its pipeline focus to extend its cash runway for another two years. The San Diego...
View ArticleClik here to view.
Perspective’s early data on lead-based radiopharma asset suggest lower dose...
In early-stage trials called dose escalation studies, drug developers usually want to test progressively higher doses of their therapies. Not Perspective Therapeutics. The radiopharma biotech announced...
View Article#CPHI24: European drugmakers look to reshore manufacturing but warn of price...
As European manufacturers localize their supply chains and production, they are also warning that drug prices could creep up if the European Commission doesn’t provide more regulation on drug...
View ArticleTeva to pay $450M to settle allegations of kickbacks and generic drug...
Generics giant Teva Pharmaceuticals will pay $450 million over six years to settle two allegations that the company violated the Anti-Kickback Statute and the False Claims Act, the Department of...
View ArticleClik here to view.
Sanofi lands on private equity firm CD&R as potential buyer of consumer...
Sanofi has chosen US private equity firm Clayton, Dubilier & Rice to advance acquisition talks for its consumer health unit, the pharma confirmed Friday. The company says it entered into...
View ArticleStealth BioTherapeutics CEO discusses surprise adcomm support for ultra-rare...
This week, Stealth BioTherapeutics CEO Reenie McCarthy faced a seemingly insurmountable roadblock with the company’s drug for the ultra-rare, fatal mitochondrial disease Barth syndrome. FDA reviewers...
View ArticleClik here to view.
Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine
Valneva is eyeing a 2027 launch for its Pfizer-partnered Lyme disease vaccine, CEO Thomas Lingelbach said Thursday during the company’s investor day. Pfizer has sole commercial responsibility for the...
View ArticlePfizer hemophilia drug marstacimab is approved by FDA
Whew. Pfizer — after a week in which it began a showdown with an activist investor, was betrayed by and then reunited with two former top executives, and ended work on an RSV drug — finally has some...
View ArticlePfizer's situation with Starboard; Meet Endpoints' 2024 Women in Biopharma;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleEli Lilly obesity drug may go back on shortage, FDA says, in win for...
The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a trade group representing large compounding pharmacies challenged the move. A...
View ArticlePfizer’s RSV vaccine has 90% efficacy against severe respiratory disease
Pfizer’s RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the company said, underscoring its potential benefits as another respiratory virus...
View ArticleRSV antibody data from Merck cut risk of illness in infants
Merck’s experimental antibody for RSV reduced infants’ risk of certain lower respiratory infections by 60.4% compared to placebo, meeting the trial’s primary endpoint. The Phase 2b/3 data, presented at...
View ArticleClik here to view.
Exclusive: Ex-Affimed CEO heads to UK nanomedicine biotech; Jami Rubin leaves...
Adi Hoess Adi Hoess describes himself as someone who “likes to build” companies focused on “challenging technologies.” It’s fitting, then, that after spending more than a decade as CEO of German...
View ArticleSupernus’ depression drug shows ‘rapid’ onset in mid-stage test
Supernus Pharmaceuticals’ mTORC1 activator has cleared a small trial in patients with major depressive disorder, potentially bringing the biotech one step closer to offering a treatment that could be...
View ArticleCVS replaces CEO Karen Lynch with PBM exec David Joyner
CVS Health is parting ways with CEO Karen Lynch as the pharmacy giant continues to struggle with problems in its insurance business. The company said Friday that it named David Joyner, the president of...
View ArticleUpdated: Pfizer ends trial of SHP2 inhibitor after similar cuts by peers
Pfizer has ended its trial of an SHP2 inhibitor that was being developed in cancer, the latest blow to the target after several other drugmakers have suffered setbacks. The New York drugmaker ended the...
View ArticleConsumer and union groups call on FTC to ‘challenge’ Novo-Catalent deal
The temperature is heating up around Novo Holdings’ acquisition of contract manufacturer Catalent, as consumer and union groups write to the Federal Trade Commission to “challenge” the deal, with a...
View Article